Skip to main content
Image removed.

Why Cordlife

Singapore’s first cord blood bank with a successful transplant track record


Technology and Quality Pioneer

AXP® II System Maximises Mononucleated Cell Recovery to Increase Transplant/Treatment Success
Automated Stem Cell Processing System

Stem cell isolation is a critical step in cord blood banking. It affects the number of stem cells that can be harvested or recovered from the cord blood. Cell recovery rates are critical because a higher number of stem cells could enhance the success of the transplant or treatment. That is why we invested in the latest automated stem cell processing technology – AXP® II System to harvest maximum stem cells for improved transplant or treatment outcomes.

AXP® II versus other processing methods

A U.S. FDA-cleared device that is capable of recovering more than 97% of Viable CD34+ stem cell, higher than other available processing systems.³ This safe, sterile and automated cord blood processing system also helps us to ensure your baby’s cord blood is processed with highly precise, reliable, and state-of-the-art technology, hence eliminating any possible cross-contamination of the cord blood unit.

Advantages of AXP® II and what it means to You, as a Parent

FeatureBenefits to You
Quality and Safety
  • Safe, sterile and automated cord blood processing system.

  • Advanced technology with new cord blood processing protocols without using hydroxyethyl starch (HES).
  • Your baby’s cord blood is processed with highly precise, reliable, and state-of-the-art technology.

  • Requires no manual processing and eliminates any possible cross-contamination of the cord blood unit.
  • Controlled, smooth, functionally closed and precise separation by an advanced optical sensor.
  • Provides automated stem cell analysis results.
  • The yield from cord blood processing is consistent, with reproducible high results.

  • Reduces the chances of manual error.
Cell Recovery
  • Despite having nearly the same total nucleated cells (TNCs), AXP-processed cord blood units contain more mononuclear cells (MNCs) than conventionally processed units.1
  • Viable CD34+ stem cell recovery is more than 97%, higher than other available processing systems.2
  • A higher recovery of CD34+ stem cells from your baby's cord blood is important, as they are correlated with a higher chance of a successful transplant.3, 4
Regulatory Approvals
  • FDA-cleared5, complies with current good tissue practice (cGTP) and good manufacturing practice (GMP).6

  • Complies with the highest quality standards for cord blood banking, such as AABB and FACT.
  • Meets international health, safety and environmental requirements to ensure consumer safety.

1 Harris DT. Collection, processing, and banking of umbilical cord blood stem cells for clinical use in transplantation and regenerative medicine. Laboratory Medicine. 2008;39(3):173-178. doi:10.1309/64G394K1M639L8A.
2 Rubinstein P. Cord blood banking for clinical transplantation. Bone Marrow Transplantation. 2009;44(10):635-642. doi:10.1038/bmt.2009.281.
3 Yoo KH, Lee SH, Kim HJ, et al. The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplantation. 2007;39(9):515-521. doi:10.1038/sj.bmt.1705629.
4 Purtill D, Smith K, Devlin S, et al. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood. 2014;124(19):2905-2912. doi:10.1182/blood-2014-03-566216.
5 Substantially equivalent 510(k) device information. U.S. Food and Drug Administration website. Accessed May 2, 2023.
6 AXP(R) II System. ThermoGenesis website. Accessed May 2, 2023.

*Kindly note that the above mentioned is general information only. Please refer to the Cordlife Service Agreement for full details and its terms and conditions. Cordlife Group Limited reserves the rights to amend or cancel any of the benefits listed above without prior notice. International quality standards may differ between the time of enrolment and time of release of your baby's cord blood unit for transplant. All reasonable efforts will be made to adhere to the prevailing standards at the time of release of your baby's cord blood unit. HLA testing and CFU Assay may or may not cease to become a mandatory quality check.Cordlife has taken added insurance coverage, to safeguard you and your family from financial loss that results from direct malpractice*.

DCR No. 5002, September 2023